Granules India Q3 FY26: revenue up 22%, PAT up 28% on consol basis

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF Explain this filing

GRANULES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.5%Reaction day

₹564.40

prior close

₹588.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%+2.3% vs market

Pharmaceuticals peers, median of 154sector-0.4%+2.9% vs sector

On the reaction day the stock moved 2.3 pts more than Nifty Smallcap 250 and 2.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.4

10m

-3.0

15m

-3.1

30m

-2.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.5+0.2+2.3-0.4+2.9

Next day

+0.1+2.1-2.0+0.0+0.1

+1.8+2.1-0.3-0.7+2.5

+1.3+2.9-1.6+0.0+1.3

-2.0+1.3-3.3-0.0-2.0

+1.2+4.2-3.1+2.4-1.2

+2.6+3.9-1.4+1.9+0.6

15d

+0.7+5.1-4.4+1.9-1.2

+2.9+3.7-0.8-0.4+3.3

+9.9-4.3+14.2-8.1+18.0

+23.5+9.1+14.4+3.9+19.6

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Granules India Q3 FY26: consolidated revenue rose 22% YoY to Rs 1,388 crore, PAT up 28% to Rs 150 crore. Standalone revenue Rs 895 crore (up 6%), PAT Rs 112 crore (up 24%). Exceptional items of Rs 26 crore relate to acquisition and litigation costs. Board approved capital raise of about Rs 1,762 crore via warrants and shares. Gagillapur USFDA impact continues.

Likely market impact

Strong Q3 revenue and earnings growth. Capital raise of about Rs 1,762 crore may dilute equity. USFDA issues remain a concern.